Four NBA franchises are running active trade scenarios on Kyrie Irving while he is still in rehabilitation for a torn ACL, which means the market has concluded that an injured 34-year-old point guard is worth trading healthy assets for -- and the variable explaining that conclusion is probably not his assist-to-turnover ratio. Irving's ACL tear came mid-season. The medical facts are public. What is less public is how much of the four-team demand reflects Anta's KAI signature line, which Irving's Chinese fan base has supported at commercial scale since 2018, when Nike declined to renew and Anta signed him instead. The KAI line has been one of Anta's stronger retail performers in mainland China since. NBA franchises do not trade into injured rosters unless the asset produces returns that do not require the player to dress.

Anta has characterized the Irving arrangement as a lifetime deal, which means his China-market commercial exposure travels with his name and not with his medical clearance. The four-team pursuit is structurally a bid on a licensing relationship: which franchise wants the Anta footprint warm through the 2026-27 commercial cycle, not which team needs a ball-handler. Irving issued a public statement about his rehabilitation; Chinese-language responses filled the first news cycle. The fan base is not paused. The Lakers' reported discussions, which include a swap built around Dalton Knecht, represent the most legible motivation if the Anta variable is what is being priced. Irving's trade destination resolves before free agency opens July 1.